StockWatch
·

Krishna Institute of Medical Sciences Ltd Q2 FY27 Results

KIMSQ2 FY27 Results
Filing
Result:Steady· Market: Flat#Margin squeeze

Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue1.3K14.0%39.9%
Total Income1.4K14.0%41.3%
Expenditure1.3K11.4%46.4%
PBT105.9090.5%9.4%
Net Profit74.6099.5%3.6%
OPM20.34%1.40pp0.86pp
NPM5.47%2.34pp1.99pp
EPS1.7972.1%7.2%
View full financials

Healthcare revenue grew a strong 39.9% YoY but adjusted PAT rose just 3.6% as OPM/NPM both contracted (20.3% vs 21.2%, 5.5% vs 7.5%), signaling margin squeeze that offsets the topline strength.

KIMS · Q2 FY27 · THE VERDICT

40% Growth, 3.6% Earnings—the Margin Test Kims Must Pass

Krishna Institute delivered a quarter of headline momentum but earnings-statement muting. Revenue surged 40%, yet profit inched only 3.6% forward. The call explains why—and whether management's confidence in margin recovery from here holds any weight.

11 Nov 2026 · 6 min read
Reported Revenue

₹1,344.4 Cr

+39.9% YoY

Reported PAT

₹74.6 Cr

+3.6% YoY

EBITDA (pre-IAS)

₹232 Cr

+17.9% YoY

EBITDA margin

17.2%

vs 18.5% Q1

On the surface, a quarter of strong momentum: volumes surged (inpatient +27%, outpatient +23.3%), Kondapur ramped 70% in three months, and the company now runs 28 hospitals operationalized across Telangana, Karnataka, AP, and Kerala. Yet the real story sits in the gap between the top line and the bottom line. Revenue up 40%, but earnings up 3.6%—the widest spread in management's recent history. That delta reveals a quarter compressed by new-unit losses, an ₹7.5 crore doubtful-debt provision, and insurance negotiation holdups that management did not flag in its Q1 call.

Where the margin went

EBITDA grew 17.9% but came in at 17.2% margin, a 130 basis-point swing vs. Q1. Three forces: (1) Doubtful debt provision ₹7.5 crore from Andhra Pradesh government business—payment delays on existing contracts forced a reserve in Q2, not previously telegraphed. (2) New-unit ramp drag: Kondapur's 70% revenue growth came with a margin collapse in the AP cluster to ~22% from 24–25% prior, because fixed costs on new programs (Vizag, Anantapur oncology expansion) front-load. (3) Insurance empanelment gaps at Thane and Mahadevapura, now 12–15 months unresolved, blocking patient flow and forcing a lower-margin mix (government business substituting). Call option fair value of ₹13.2 crore in Q2 was booked below EBITDA as other income, inflating headline EBITDA by ~140 basis points.

Q2 FY27 Key Metrics
-150.39-80.16-9.9460.2939.9Revenue growth3.6PAT growth17.9EBITDA growth-130Margin compression
40% top-line growth offset by 130bp margin headwind from ramps, PBDT provision, and call option accounting.
Management's claims vs. what holds up

Consolidated revenue ₹1,344 Cr, +39.9% YoY

Delivered ₹1,344.4 Cr matches guidance precisely

Supported

EBITDA margin 20.5% in Q2, stable vs Q1's 20.1%

Consolidated margin fell 130bp; AP cluster margin dipped to ~22%. Stability claim masks compression in core units.

Overstated

Kondapur revenue grew 70% in 3 months; ramp on track

₹623 Cr Q1 → ₹700 Cr Q2 confirms 70% growth; but EBITDA margin fell due to fixed costs, new programs

Supported (on growth); margin recovery unproven

Q2 is the bottom quarter for losses in new units; margins return to 30% in 3–4 quarters

Management assertion; similar claims made for Thane (insurance blocks) and Mahadevapura (14-month ramp). No quantified milestone or proof of prior ramp success.

Overstated

Doubtful debt is temporary; reversal expected Q3 onwards

₹7.5 Cr provision in Q2 not flagged in Q1 call. Government payment delays are structural, not temporary. Reversal contingent on timing, not guaranteed.

Overstated

What changed on this call

New facts or shifts in tone
  • Doubtful debt provision ₹7.5 Cr materialized in Q2 (not flagged in Q1)

  • AP cluster margin fell to ~22% despite 40% top-line growth; recovery pushed to 3–4 quarters vs. prior 'next quarter' tone

  • Insurance empanelment (Thane, Mahadevapura) still unresolved after 12–15 months; no clear end date despite management's prior optimism

  • Sarvottam Healthcare acquisition at ₹80 Cr for 51% (₹157 Cr implied valuation for ₹1.2–1.5 Cr EBITDA = 105–131x multiple) disclosed as new portfolio risk

  • Capex plan clarified at ₹1,100 Cr over 18 months (Secunderabad, Rajahmund, Kondapur); management reaffirmed no new hospital until stabilization (FY28+)

The bull-bear ledger

  • Broad-based volume momentum: inpatient +27% YoY, outpatient +23.3%, ARPU +14.9% per bed

  • Kondapur ramp-up documented (70% in 3 months); flagship hospital on trajectory to ₹1,200 Cr revenue (5-year target)

  • Network expanded to 28 hospitals operationalized; leverage stable post-QIP at ~1.9x EBITDA

  • Reported profit leans on non-recurring call option gains; adjusted PAT muted

  • Margin compression in new units and AP cluster unresolved; management's 'Q2 is bottom' claim lacks prior execution proof

  • Insurance empanelment delays (Thane, Mahadevapura) now 12–15 months old; structural risk, not temporary

  • Sarvottam at 105–131x EBITDA; integration risk with 6 concurrent acquisitions/O&M deals + 28 hospitals simultaneously

Risks, ranked by how much they should concern a holder

What can upend the bull case

Insurance empanelment delays (Thane, Mahadevapura unresolved 12–15 months)

High

Patient flow blocked at two large new units. Forces lower-margin government mix. No clear resolution timeline despite management's prior optimism. Each quarter delayed costs ₹1–2 Cr+ in foregone EBITDA.

Margin recovery timeline (3–4 quarters to 30% at AP/Kondapur)

High

Management claim lacks quantified milestones or prior ramp precedent. If insurance delays persist or new programs drag longer (as with Thane), recovery pushed beyond FY27 end. Earnings miss risk.

Sarvottam acquisition at 53–67x EBITDA (₹80 Cr for ₹1.2–1.5 Cr EBITDA)

High

Extraordinarily high entry multiple. Management confident in ramp to ₹7–8 Cr/month but execution unproven. 6 concurrent acquisitions + 28 hospitals create integration bandwidth risk; overpayment likely if ramp fails.

Doubtful debt provision reversal contingent on government payment timings

Medium

₹7.5 Cr provision in Q2 is structural (AP government payment delays), not temporary. If delays extend into Q4, reversal won't land; ₹7.5 Cr earnings miss.

Anti-cancer drug trade margin regulation (disclosure Nov 9th) impacts oncology pricing

Medium

Final details not yet disclosed. Oncology not a large revenue driver, but high-margin segment. If margin cap lands, could reset KIMS' regional margin targets downward.

Capex intensity and leverage if revenue ramps slower

Medium

₹1,100 Cr capex over 18 months; ₹3,600 Cr debt raised. If new hospitals ramp slower (insurance, occupancy miss), leverage will remain elevated; financial flexibility crimped.

How the market is positioned

KIMS trades at ₹721.65, -15.89% from its all-time high of ₹858, but +25.33% from the 52-week low. The stock sits above its 20-day moving average (₹702) but below the 50-day (₹734.91) and 200-day (₹729.17) averages—a neutral trend pattern. RSI at 51.1 signals no overbought or oversold condition. Volume is normal, suggesting neither institutional capitulation nor retail enthusiasm. Ownership remains stable: FII at 14.74% (up 17bp QoQ), DII at 34.43% (up 193bp), and promoter at 32.50% (down 161bp). The modest promoter trim near the 52-week low is notable but not alarming. The street's neutral pricing—neither punishing the miss nor rewarding the growth—reflects honest skepticism on margin recovery. The drawdown from ATH is justified given execution risk; the stock is neither oversold enough to be a forced-buy nor expensive enough to be a short.

The debate

What to watch next
  • 1 · Anti-cancer drug regulation (Nov 9 disclosure)

    Final details on trade margin cap and KIMS' mitigation plan. If oncology margin cut >5%, reset regional EBITDA margin guidance downward.

  • 2 · Q3 insurance empanelment progress (Thane, Mahadevapura)

    First concrete evidence whether delays resolve by end-calendar-year. Absence of empanelment in Q3 signals structural negotiation failure; signals margin recovery miss.

  • 3 · Doubtful debt reversal trajectory (Q3 onwards)

    If AP government payments resume as expected, ₹7.5 Cr provision should reverse Q3. Absence of reversal signals government liquidity crisis; another quarter of drag.

  • 4 · Sarvottam ramp-up progress (monthly EBITDA exiting Q3, occupancy trend)

    Management claimed ₹1.2–1.5 Cr/month current EBITDA and ₹7–8 Cr/month ramp target. First read on execution: occupancy, revenue per bed, new admissions.

Krishna Institute delivered the quarter management telegraphed—40% revenue growth with a margin test it did not all anticipate. The PBDT provision and insurance delays are not new problems (they were flagged in prior calls) but their magnitude in Q2 (₹7.5 Cr drag) was. The company is neither in crisis nor firing on all cylinders; it is in transition: ramping new units, absorbing integrations, and betting that margin stabilization lands in Q3–Q4. The market's neutral stance is correct—neither a buy nor a sell until management proves it can execute on margin recovery and navigate the insurance empanelment hurdles. Watch the Nov 9 drug regulation disclosure and Q3 results for concrete progress on Thane/Maha empanelment and PBDT reversal. The number to track is adjusted (non-call option, non-PBDT) EBITDA per hospital—it will show whether new units are indeed bottoming or rolling into FY28. Hold until Q3.

Informational and educational content only. Not investment advice.